Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Clinical Data Positive For Korean Biosimilars

This article was originally published in PharmAsia News

Executive Summary

New clinical study data have been presented to a major international meeting on Samsung Bioepis and Celltrion's major biosimilar contenders as well as Boryung Pharm's hypertension therapy, all of which are South Korean drugs carrying their developer’s ambitions of overseas market launches or expansion.

You may also be interested in...



Samsung Prepping For First Biosimilar Launch

Samsung Bioepis' biosimilar version of Amgen's rheumatoid arthritis blockbuster Enbrel (etanercept) is set to become the firm’s first biosimilar product to hit the market, possibly being released in South Korea late this year and in Europe in the first half of next year.

Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights

Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio

AriBio Progresses Novel Alzheimer's Contender Despite Mixed Phase II

Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?

Topics

Related Companies

UsernamePublicRestriction

Register

SC088940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel